<DOC>
	<DOCNO>NCT02550548</DOCNO>
	<brief_summary>This project design advance understand incretin effect health disease . This system gut-islet linkage essential normal glucose tolerance , impaired T2DM , amenable therapeutic intervention . However , important gap understand incretin function limit application system ; project address several . A secondary , critical aspect research focus inter-individual variation physiology incretin system . This novel direction research field critical advance concept individualize medical care diabetes establish whether physiologic basis predict existence responder non-responders incretin therapy . Currently , describe Aim 1 grant protocol registration . While Aim 2 3 described grant , Aim 1 conduct first result Aim / publication result field may affect approach Aims 2 3 .</brief_summary>
	<brief_title>Incretin Action Physiology Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>healthy volunteer fast glucose value ≤ 95 mg/dL A1c ≤ 5.7 % first degree family member T2DM Family personal history diabetes , include gestational diabetes . Subjects : active infectious , malignant inflammatory condition ; unstable angina uncompensated heart failure ; pulmonary disorder include COPD asthma ; malabsorptive GI disease ; significant hepatic disease ; renal insufficiency ( eGFR &lt; 60 ml/kg/min ) ; anemia ( hematocrit &lt; 34 % ) ; pregnancy uncontrolled hypertension Subjects exclude require daily medication alter glucose metabolism GI function ( glucocorticoid , psychotropics , narcotic , metoclopramide ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Incretins</keyword>
	<keyword>GLP-1</keyword>
	<keyword>GIP</keyword>
	<keyword>hyperglycemic clamp</keyword>
</DOC>